Ziprasidone-induced cognitive enhancement in schizophrenia: Specificity or pseudospecificity?

Schizophrenia Research

Volumn 87, Issue 1-3, 2006, Pages 181-184

  Malhotra, Anil K ^a,b   Burdick, Katherine E ^a,b   Razi, Kamran ^a   Bates, John A ^a   Sanders, Michael ^a   Kane, John M ^a,b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Cognition; Memory; Schizophrenia; Ziprasidone

Indexed keywords

ARIPIPRAZOLE; BENZODIAZEPINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL ARTICLE; COGNITION; FEMALE; HUMAN; MALE; MEMORY; NEUROLOGIC EXAMINATION; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TASK PERFORMANCE;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; COGNITION; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PIPERAZINES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; THIAZOLES;

EID: 33748916479     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2006.05.015     Document Type: Article

References (15)

1. Bilder R.M., Goldman R.S., Robinson D., Reiter G., Bell L., Bates J.A., Pappadopulos E., Willson D.F., Alvir J.M., Woerner M.G., Geisler S., Kane J.M., and Lieberman J.A. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am. J. Psychiatry 157 4 (2000) 549-559
2. Bilder R.M., Goldman R.S., Volavka J., Czobor P., Hoptman M., Sheitman B., Lindenmayer J.P., Citrome L., McEvoy J., Kunz M., Chakos M., Cooper T.B., Horowitz T.L., and Lieberman J.A. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am. J. Psychiatry 159 6 (2002) 1018-1028
3. Bowie C.R., and Harvey P.D. Cognition in schizophrenia: Impairments, determinants, and functional importance. Psychiatr. Clin. North Am. 28 3 (2005) 613-633
4. Cana F. Mechanisms of action of atypical antipsychotics. CNS Spectr. 10 8 (2005) 5-11
5. Harvey P.D., Moriarty P.J., Serper M.R., Schnur E., and Lieber D. Practice-related improvement in information processing with novel antipsychotic treatment. Schizophr. Res. 46 2-3 (2000) 139-148
6. Harvey P.D., Moriarty P.J., Bowie C., Friedman J.I., Parrella M., White L., and Davis K.L. Cortical and subcortical cognitive deficits in schizophrenia: convergence of classifications based on language and memory skill areas. J. Clin. Exp. Neuropsychol. 24 1 (2002) 55-66
7. Harvey P.D., Green M.F., McGurk S.R., and Meltzer H.Y. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology (Berl) 169 3-4 (2003) 404-411
8. Harvey P.D., Meltzer H., Simpson G.M., Potkin S.G., Loebel A., Siu C., and Romano S.J. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr. Res. 66 2-3 (2004) 101-113
9. Harvey P.D., Bowie C.R., and Antony L. Is cognitive improvement associated with switching to a new atypical antipsychotic sustained over time? A six-month extension study of patients switched to ziprasidone. Clin. Neuropsychol. 2 2 (2005) 110-115
10. Ichikawa J., Dai J., O'Laughlin I.A., Fowler W.L., and Meltzer H.Y. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 26 3 (2002) 325-339
11. Pepeu G., and Giovannini M.G. Changes in acetylcholine extracellular levels during cognitive processes. Learn. Mem. 11 1 (2004) 21-27
12. Perry E., Walker M., Grace J., and Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness?. Trends Neurosci. 22 6 (1999) 273-280
13. Spreen O., and Strauss E. A Compendium of Neurological Tests: Administration, Norms, and Commentary. 2nd ed. (1998), Oxford University Press, New York
14. Weiden P.J., Simpson G.M., Potkin S.G., and O'Sullivan R.L. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia. J. Clin. Psychiatry 64 5 (2003) 580-588
15. Winkler J., Suhr S.T., Gage F.H., Thal L.J., and Fisher L.J. Essential role of neocortical acetylcholine in spatial memory. Nature 375 6531 (1995) 484-487